Immunotherapy has been less effective in prostate cancer vs. certain other cancers. However, a new approach called PSCA CAR-T cell therapy shows encouraging results in a PCF-funded early-phase clinical trial. PCF sat down with lead researchers Drs. Tanya Dorff and Saul Priceman of City of Hope to discuss their findings. Watch the video to learn more about:
- The need to develop a new prostate cancer treatment
- How a patient’s immune system can be leveraged to fight prostate cancer
- Improved patient response to CAR T cell treatment by combining with chemotherapy
- How to talk to your doctor about your treatment options, including clinical trials